Mammaglobin A, a novel marker of minimal residual disease in early stages breast cancer
Jazyk angličtina Země Slovensko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
15254674
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mammaglobin A MeSH
- nádorové biomarkery analýza MeSH
- nádorové proteiny analýza biosyntéza MeSH
- nádory kostní dřeně diagnóza sekundární MeSH
- nádory prsu patologie MeSH
- polymerázová řetězová reakce s reverzní transkripcí MeSH
- prognóza MeSH
- reziduální nádor MeSH
- senioři MeSH
- senzitivita a specificita MeSH
- staging nádorů * MeSH
- uteroglobin analýza biosyntéza MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- mammaglobin A MeSH
- nádorové biomarkery MeSH
- nádorové proteiny MeSH
- SCGB2A2 protein, human MeSH Prohlížeč
- uteroglobin MeSH
Mammaglobin A, in contrast to other factors, is a breast specific member of uteroglobin gene family. Expression is restricted to normal and neoplastic breast epithelium. A highly homologous mammaglobin B is not specific to breast tissue. In this pilot feasibility study we examined expression of both markers for minimal residual disease in the bone marrow of patients with breast cancer. We obtained bone marrow aspirates of 34 patients with stage I (41%), II (56%) and III (3%) breast cancer who underwent either immediate complete resection of the tumor or neoadjuvant therapy with subsequent curative surgery. mRNA was isolated using QIAamp RNA blood mini kit (Qiagen). Subsequently two-step nested RT-PCR for the expression of mammaglobin A and mammaglobin B was performed. Mammaglobin A was detected in samples from 4 (12%) out of 34 patients. None of the specimens was positive for mammaglobin B. With a median follow-up of 21 month we observed only 2 recurrences, one in patient with mammaglobin A positive bone marrow.RT-PCR assay for mammaglobin A may be a useful tool for detection of occult breast cancer cells in the bone marrow. Clinical and prognostic relevance of minimal residual disease should be further investigated.
